Stefania Di Marco
Main position/role: Scientific Director and Qualified Person, Advent S.r.l. (part of the IRBM group)
|Stefania has been working for the past 12 years in clinical research and in good manufacturing practices of adenovirus-based vaccines for Infectious Diseases (HCV, malaria, RSV, HIV, Ebola, leishmaniasis, rabies, HBV, RVF and SARS-CoV-2). She has 57 publications and four patents and 12-year experience in the evaluation of EU-funded research programmes (FP7, H2020, HORIZON, Eureka-Eurostars). Stefania worked for 18 years in preclinical drug discovery, employing molecular biology, biochemistry and X-ray crystallography (Novartis, Basel and IRBM-Merck, Pomezia).
She graduated in Biological Sciences in 1989, from the University of Rome La Sapienza and obtained a PhD in Cellular and Molecular Biology in 1994, from the University of Rome Tor Vergata.